Galectin Therapeutics Inc (GALT)
3.60
+0.15
(+4.35%)
USD |
NASDAQ |
Apr 29, 16:00
3.615
+0.02
(+0.42%)
After-Hours: 20:00
Galectin Therapeutics Net Income (Quarterly): -9.997M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -9.997M |
| September 30, 2023 | -10.43M |
| June 30, 2023 | -9.114M |
| March 31, 2023 | -11.53M |
| December 31, 2022 | -10.63M |
| September 30, 2022 | -8.597M |
| June 30, 2022 | -9.613M |
| March 31, 2022 | -9.932M |
| December 31, 2021 | -7.221M |
| September 30, 2021 | -8.52M |
| June 30, 2021 | -8.449M |
| March 31, 2021 | -6.338M |
| December 31, 2020 | -7.852M |
| September 30, 2020 | -5.943M |
| June 30, 2020 | -6.114M |
| March 31, 2020 | -3.556M |
| December 31, 2019 | -5.137M |
| September 30, 2019 | -2.784M |
| June 30, 2019 | -2.998M |
| March 31, 2019 | -2.375M |
| December 31, 2018 | -3.05M |
| September 30, 2018 | -2.752M |
| June 30, 2018 | -3.84M |
| March 31, 2018 | -4.258M |
| December 31, 2017 | -2.382M |
| Date | Value |
|---|---|
| September 30, 2017 | -4.408M |
| June 30, 2017 | -4.508M |
| March 31, 2017 | -4.937M |
| December 31, 2016 | -4.591M |
| September 30, 2016 | -4.526M |
| June 30, 2016 | -5.519M |
| March 31, 2016 | -6.80M |
| December 31, 2015 | -4.671M |
| September 30, 2015 | -5.887M |
| June 30, 2015 | -4.643M |
| March 31, 2015 | -4.826M |
| December 31, 2014 | -3.731M |
| September 30, 2014 | -3.518M |
| June 30, 2014 | -3.429M |
| March 31, 2014 | -5.11M |
| December 31, 2013 | -2.799M |
| September 30, 2013 | -3.542M |
| June 30, 2013 | -2.544M |
| March 31, 2013 | -3.203M |
| December 31, 2012 | -2.376M |
| September 30, 2012 | -2.689M |
| June 30, 2012 | -2.66M |
| March 31, 2012 | -1.95M |
| December 31, 2011 | -3.368M |
| September 30, 2011 | -2.028M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-11.53M
Minimum
Mar 2023
-2.784M
Maximum
Sep 2019
-7.619M
Average
-8.449M
Median
Jun 2021
Net Income (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -112.19M |
| Viking Therapeutics Inc | -27.36M |
| 89bio Inc | -40.24M |
| Terns Pharmaceuticals Inc | -21.02M |
| Enanta Pharmaceuticals Inc | -33.41M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.561M |
| EPS Diluted (Quarterly) | -0.16 |
| Enterprise Value | 271.16M |
| Earnings Yield | -20.56% |